The North America In Vitro Toxicity Testing Market is expected to witness market growth of 10.1% CAGR during the forecast period (2022-2028).
In vitro toxicology examines the harmful characteristics of substances and combinations utilizing cells sustained or developed in controlled laboratory settings. This allows everyone to analyze xenobiotic toxicity at the cellular level without the interference of multiple physiological systemic effects which are frequently found in whole organisms. Primary cultures of cells from certain tissues, such as the liver for xenobiotic biotransformation, kidney or gills for ionic homeostasis, and nerve cells for neurotransmitter signaling effects, could be used to investigate specific cellular processes.
By adopting technologies employed by the pharmaceutical companies in human clinical trials, it may be feasible to get more understanding into individual in vivo mechanisms and processes, as well as assess the significance of in vitro identified mechanisms such as, micro-dosing and tracing studies. Data extension from a healthy to a clinical condition may be possible with a greater knowledge of the processes and pathways involved.
Markers and marker statuses with sufficient ability to predict toxicity including potency and efficacy in the case of medications are in high demand. Specific gene clusters have been found and examined for a variety of disorders such as allergies, chronic diseases, and cancer. Simulation of gene clusters has improved the insight into the mechanisms underlying clinical diseases, and diagnostic indicators have been discovered.
Technical developments and favorable regulatory changes have spurred the advancement of innovative, cost-effective testing for evaluating medication, device, chemical, and cosmetic safety in North America over the last few years. Clients can build toxicological analyses of biopharmaceuticals, medical equipment, cosmetics, and chemicals due to a major increase in equipment and the continued growth of laboratory capacities across the region. The extension of current cell/tissue flow cytometry, culture abilities, and spectrometry facilities, as well as the adoption of rapid detection, multiplexing, and automatic technologies for biomarkers analysis, are all part of these initiatives.
According to the United Nations Globally Harmonized System of Classification and Labeling of Chemicals (GHS), a skin sensitizer, is a substance or mixture that causes an allergic reaction when it comes into contact with the skin. A chemical's propensity to elicit allergic contact dermatitis, a local skin response characterized by redness, swelling, and itching, is determined through skin sensitization testing.
The US market dominated the North America In Vitro Toxicity Testing Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $10.0 billion by 2028. The Canada market is experiencing a CAGR of 12.6% during (2022-2028). Additionally, The Mexico market is expected to is expected to witness a CAGR of 11.6% during (2022-2028).
Based on Type, the market is segmented into Absorption, Toxic Substances, and Dose. Based on Technology, the market is segmented into Cell Culture Technologies, High Throughput Technologies, and Toxicogenomics. Based on End User, the market is segmented into Cosmetics & Households Products, Pharmaceuticals Industry, Food Industry, Chemicals, and Industry. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., General Electric (GE) Co., AstraZeneca PLC, Catalent, Inc., Laboratory Corporation of America Holdings, Acacia Pharma Group Plc, GlaxoSmithKline PLC, Helsinn Healthcare SA., and Heron Therapeutics, Inc.
By Type
By Country
In vitro toxicology examines the harmful characteristics of substances and combinations utilizing cells sustained or developed in controlled laboratory settings. This allows everyone to analyze xenobiotic toxicity at the cellular level without the interference of multiple physiological systemic effects which are frequently found in whole organisms. Primary cultures of cells from certain tissues, such as the liver for xenobiotic biotransformation, kidney or gills for ionic homeostasis, and nerve cells for neurotransmitter signaling effects, could be used to investigate specific cellular processes.
By adopting technologies employed by the pharmaceutical companies in human clinical trials, it may be feasible to get more understanding into individual in vivo mechanisms and processes, as well as assess the significance of in vitro identified mechanisms such as, micro-dosing and tracing studies. Data extension from a healthy to a clinical condition may be possible with a greater knowledge of the processes and pathways involved.
Markers and marker statuses with sufficient ability to predict toxicity including potency and efficacy in the case of medications are in high demand. Specific gene clusters have been found and examined for a variety of disorders such as allergies, chronic diseases, and cancer. Simulation of gene clusters has improved the insight into the mechanisms underlying clinical diseases, and diagnostic indicators have been discovered.
Technical developments and favorable regulatory changes have spurred the advancement of innovative, cost-effective testing for evaluating medication, device, chemical, and cosmetic safety in North America over the last few years. Clients can build toxicological analyses of biopharmaceuticals, medical equipment, cosmetics, and chemicals due to a major increase in equipment and the continued growth of laboratory capacities across the region. The extension of current cell/tissue flow cytometry, culture abilities, and spectrometry facilities, as well as the adoption of rapid detection, multiplexing, and automatic technologies for biomarkers analysis, are all part of these initiatives.
According to the United Nations Globally Harmonized System of Classification and Labeling of Chemicals (GHS), a skin sensitizer, is a substance or mixture that causes an allergic reaction when it comes into contact with the skin. A chemical's propensity to elicit allergic contact dermatitis, a local skin response characterized by redness, swelling, and itching, is determined through skin sensitization testing.
The US market dominated the North America In Vitro Toxicity Testing Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $10.0 billion by 2028. The Canada market is experiencing a CAGR of 12.6% during (2022-2028). Additionally, The Mexico market is expected to is expected to witness a CAGR of 11.6% during (2022-2028).
Based on Type, the market is segmented into Absorption, Toxic Substances, and Dose. Based on Technology, the market is segmented into Cell Culture Technologies, High Throughput Technologies, and Toxicogenomics. Based on End User, the market is segmented into Cosmetics & Households Products, Pharmaceuticals Industry, Food Industry, Chemicals, and Industry. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., General Electric (GE) Co., AstraZeneca PLC, Catalent, Inc., Laboratory Corporation of America Holdings, Acacia Pharma Group Plc, GlaxoSmithKline PLC, Helsinn Healthcare SA., and Heron Therapeutics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Absorption
- Toxic Substances
- Dose
- Cell Culture Technologies
- High Throughput Technologies
- Toxicogenomics
- Cosmetics & Households Products
- Pharmaceuticals Industry
- Food Industry
- Chemicals Industry
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc.
- General Electric (GE) Co.
- AstraZeneca PLC
- Catalent, Inc.
- Laboratory Corporation of America Holdings
- Acacia Pharma Group Plc
- GlaxoSmithKline PLC
- Helsinn Healthcare SA.
- Heron Therapeutics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. North America In Vitro Toxicity Testing Market by Type
Chapter 4. North America In Vitro Toxicity Testing Market by Technology
Chapter 5. North America In Vitro Toxicity Testing Market by End User
Chapter 6. North America In Vitro Toxicity Testing Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- General Electric (GE) Co.
- AstraZeneca PLC
- Catalent, Inc.
- Laboratory Corporation of America Holdings
- Acacia Pharma Group Plc
- GlaxoSmithKline PLC
- Helsinn Healthcare SA.
- Heron Therapeutics, Inc.
Methodology
LOADING...
